Mealtime inhaled insulin lowers fasting glucose: A look at possible explanations [1]

Diabetologia

Volumn 48, Issue 12, 2005, Pages 2682-2683

  DeVries, J H ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INSULIN ZINC SUSPENSION;

ANTIBODY PRODUCTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFICACY; DRUG FORMULATION; FEEDING BEHAVIOR; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; INFUSION PUMP; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN SENSITIVITY; LETTER; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; CLINICAL TRIALS; EATING; FASTING; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN ANTIBODIES; POSTPRANDIAL PERIOD; TIME FACTORS;

EID: 28444442713     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-005-0027-0     Document Type: Letter

References (11)

1. Quattrin T, Belanger A, Bohannon NJ, Schwartz SL (2004) Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 27:2622-2627
2. Skyler JS, Weinstock RS, Raskin P et al (2005) Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 28:1630-1635
3. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U (2004) Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 27:162-167
4. Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA et al (2005) Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 28:1077-1082
5. Edgerton DS, Neal DW, Scott M et al (2005) Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Diabetes 54:1164-1170
6. Cherrington AD, Neal DW, Edgerton DS et al (2004) Inhalation of insulin in dogs: assessment of insulin levels and comparison to subcutaneous injection. Diabetes 53:877-881
7. DeVries JH, Snoek FJ, Kostense PJ, Heine RJ (2003) Improved glycaemic control in type 1 diabetes patients following participation per se in a clinical trial - mechanisms and implications. Diabetes Metab Res Rev 19:357-362
8. Siebenhofer A, Plank J, Berghold A et al (2004) Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 47:1895-1905
9. Olsen CL, Chan E, Turner DS et al (1994) Insulin antibody responses after long-term intraperitoneal insulin administration via implantable programmable insulin delivery systems. Diabetes Care 17:169-176
10. Jeandidier N, Boivin S, Sapin R et al (1995) Immunogenicity of intraperitoneal insulin infusion using programmable implantable devices. Diabetologia 38:577-584
11. Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A (2005) Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 90:3287-3294